“25 | EARLY AND MAINTAINED TREAT-TO-TARGET RESPONSE WITH IXEKIZUMAB UP TO 5 YEARS IN MODERATE-TO-SEVERE PSORIASIS: A POST-HOC ANALYSIS OF UNCOVER-3: E. Filippi1, A. Armstrong2, J. F. Merola3, M. Megna4, X. Man5, M. Honma6, J-M. Carrascosa7, R. Chughtai7, K. Fotiou8, S. Sabatino8, M. Ngantcha8, A. Pinter9 | 1Eli Lilly Italia S.p.A, Florence, Italy; 2University of California, Los Angeles, CA, USA; 3University of Texas Southwestern Medical Center, Dallas, TX, USA; 4University of Naples Federico II, Naples, Italy; 5Zhejiang University, Hangzhou, China; 6Asahikawa Medical University, Asahikawa, Japan; 7Hospital Germans Trias, Universitat Autònoma de Barcelona, Barcelona, Spain; 8Eli Lilly and Company, Indianapolis, IN, USA; 9University Hospital Frankfurt, Frankfurt, Germany” (2026) Dermatology Reports, 18(s1). doi:10.4081/dr.2026.11087.